Drugs / mRNA-2808
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07116616 | Sep 2025 → Jun 2030 expected | refractory plasma cell neoplasm | ModernaTX, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-25 | ModernaTX, Inc. | Results Moderna Science Day Highlights Expanding Potential of mRNA Platform q4web.com ↗
Advancement of mRNA-2151 is supported by an encouraging early clinical signal with mRNA-2808. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-25 | ModernaTX, Inc. | Moderna Science Day Highlights Expanding Potential of mRNA Platform q4web.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-2808 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07116616 ↗ |